Related Experiment Video

Updated: Apr 25, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K

Emodin inhibits breast cancer cell proliferation through the ERα-MAPK/Akt-cyclin D1/Bcl-2 signaling pathway

Jia-Qi Sui1, Kun-Peng Xie, Wei Zou

  • 1School of Life Science, Liaoning Normal University, Liaoning Provincial Key Laboratory of Biotechnology and Drug Discovery, Dalian, China

Asian Pacific Journal of Cancer Prevention : APJCP
|August 16, 2014
PubMed
Abstract

Insights

Emodin inhibits human breast cancer cell growth by blocking the estrogen (E2) signal pathway. This natural compound affects both genomic and non-genomic pathways, offering potential therapeutic strategies for estrogen receptor-positive breast cancers.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Estrogen signaling plays a crucial role in the proliferation of hormone-dependent breast cancers.
  • Emodin, a natural compound, has shown potential anti-cancer properties.
  • Investigating emodin's effects on estrogen-sensitive breast cancer cells is vital for developing new therapies.

Purpose of the Study:

  • To investigate the effects of emodin on human breast cancer cell lines (MCF-7 and MDA-MB-231) in vitro.
  • To elucidate the impact of emodin on the estrogen (E2) signaling pathway.
  • To determine emodin's influence on cell proliferation, apoptosis, and cell cycle progression.

Main Methods:

  • Cell proliferation was assessed using MTT assays.
  • Apoptosis was analyzed by flow cytometry (FCM).
  • Protein expression levels of estrogen receptor α (ERα), cyclin D1, B-cell lymphoma-2 (Bcl-2), mitogen-activated protein kinases (MAPK), and phosphatidylinositol 3-kinases (PI3K) were determined via Western blotting. Transcriptional activity of ERα was evaluated using luciferase assays.

Main Results:

  • Emodin inhibited E2-induced proliferation and anti-apoptotic effects in MCF-7 cells.
  • Emodin treatment led to cell cycle arrest at the G0/G1 phase.
  • Emodin blocked E2's effects on ERα expression and transcriptional activity, downregulating cyclin D1 and Bcl-2 (genomic pathway) and decreasing PI3K/Akt protein expression (non-genomic pathway).

Conclusions:

  • Emodin demonstrates inhibitory effects on MCF-7 cell proliferation.
  • These inhibitory effects are mediated by the modulation of both non-genomic and genomic estrogen signaling pathways.
  • Emodin represents a potential therapeutic agent for breast cancer treatment targeting estrogen signaling.

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

12.4K
An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

7.8K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K